Comparative Pharmacology
Head-to-head clinical analysis: QUIBRON T SR versus VOSPIRE ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUIBRON T SR versus VOSPIRE ER.
QUIBRON-T/SR vs VOSPIRE ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular cAMP, and antagonizing adenosine receptors.
Vospire ER (albuterol sulfate) is a beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via activation of adenylyl cyclase, leading to bronchodilation.
200-400 mg orally every 12 hours; extended-release tablets. Initial dose 200 mg every 12 hours; may increase by 200 mg daily every 3-7 days based on serum theophylline levels (target 5-15 mcg/mL). Maximum 800 mg/day.
Oral: 30-60 mg once daily in the morning, with or without food. Maximum dose: 60 mg/day.
None Documented
None Documented
Terminal t1/2: 3-12 hours (adults); 1-9 hours (children); prolonged in cirrhosis (up to 30 hours), heart failure, elderly. Clinical context: Narrow therapeutic index (5-15 mcg/mL); dosing interval adjusted based on t1/2.
Terminal elimination half-life of vospire ER is approximately 12-15 hours. This prolonged half-life supports once-daily dosing and provides sustained bronchodilation over the dosing interval.
Renal: ~10% unchanged; Hepatic metabolism (CYP1A2, CYP3A4): 90% to inactive metabolites (1,3-dimethyluric acid, 3-methylxanthine, 1-methyluric acid). Biliary/fecal: minimal (<5%).
Primarily renal (approximately 75% as unchanged drug and metabolites) and biliary/fecal (approximately 25%).
Category C
Category C
Xanthine Bronchodilator
Xanthine Bronchodilator